Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathologic Complete Response (pCR) — 6 patients
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=58 Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 27 participants
Phase 2 N=76 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Breast Cancer · Chest Wall Disease
Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants
Phase 2 N=32 Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 16 Months
Phase 2 N=29 Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery — 56 percentage of…
Phase 2 N=61 Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=103 Ixabepilone + Carboplatin Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Phase 2 N=60 Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Breast Cancer
Primary: Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and…
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Phase 2 N=63 ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Breast Cancer · Metastatic Breast Cancer · BRCA1 Gene Mutation
Primary: Objective Response Rate (ORR) of ABT-888 and Temozolomide (TMZ) in Metastatic Breast Cancer — 4; 3 Participants
Phase 2 N=41 Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Breast Cancer
Primary: Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat…
Phase 2 N=71 Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Phase 2 N=43 Neoadjuvant Treatment of Breast Cancer
Breast Cancer
Primary: Overall Clinical Response to the Dose Dense Regimen — 43 Participants
Phase 2 N=144 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
Phase 2 N=32 Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response — 62.5 Percentage of participants
Phase 2 N=215 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathological Complete Response Rate — 35; 24 Participants — p=0.019
Phase 2 N=40 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Phase 2 N=31 Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative Metastatic Breast Cancer — 6 participants
Phase 2 N=60 Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Breast Cancer
Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants
Phase 2 N=30 Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Breast Cancer
Primary: Proportion of Patients Experiencing Grade 3 or 4 Diarrhea as Measured by NCI CTCAE v3.0 — 43 percentage of patients
Phase 2 N=23 Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Phase 2 N=40 DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
Advanced Breast Cancer · HER2-positive Breast Cancer · Brain Metastases
Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants
Phase 2 N=15 Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Breast Cancer
Primary: Phase II: The Number of Subjects Exhibiting Pathologic Complete Response to Neoadjuvant Treatment With Sunitinib/Paclitaxel/Carboplatin — 12 participants
Phase 2 N=27 Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
Breast Cancer
Primary: Number of Participants With Complete Pathologic Response. — 13 participants
Phase 2 N=78 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) of MTD/Phase II Patients — 4.0 months